Atherectomy Device Market Size, Share, and Trends Analysis | Global | 2025-2032 | Includes: Laser Atherectomy Devices and Mechanical Atherectomy Devices

Global Atherectomy Device Market Report

The global atherectomy device market was valued at $915 million in 2025. Over the forecast period, the market is expected to grow at a CAGR of 1.3% to reach approximately $1.0 billion by 2032.

• The full report suite on the global market for atherectomy devices covers seven geographical regions: North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa. For each region, the report provides market valuation, unit analysis and average selling price data, while also extending projections through 2032 to provide a detailed view of how the market is expected to develop over time. As with the attached example, this report is structured to move from market sizing into drivers, limiters, segmentation, competition and strategic use cases in a clear and practical format .

This report focuses on the global market for atherectomy devices and includes detailed analysis of laser atherectomy devices and mechanical atherectomy disposables. Across these segments, the report quantifies unit sales, procedure numbers, average selling prices, total market value, market shares, growth trends and forecasts. It also includes recent mergers and acquisitions, company profiles, product portfolios and analysis of leading competitors.

Overall, the atherectomy device market remains clinically important and strategically relevant, but it is not a high-growth mass-volume category. Instead, it is a focused market driven by complex cases, specific lesion types and physicians who value plaque modification as part of a broader endovascular treatment strategy.

Market Overview

The global atherectomy device market includes devices used to remove plaque from peripheral blood vessels during endovascular procedures. Unlike standard balloon angioplasty, which expands the vessel through mechanical dilation, atherectomy actively removes or debulks the lesion. This can improve luminal gain, reduce plaque burden and prepare the vessel for additional treatment, such as balloon angioplasty or drug-coated balloon use.

Atherectomy is used across a range of peripheral vascular applications, but it is especially relevant in cases where calcification, lesion complexity or vessel size make standard balloon-only treatment less effective. This includes both above-the-knee and below-the-knee procedures. Because plaque removal can improve vessel preparation, atherectomy has become an important part of treatment planning for many physicians managing more difficult peripheral arterial disease cases.

A major trend in this market is the shift toward minimally invasive and precision-based intervention. Newer atherectomy systems are being designed with better navigational control, improved plaque removal capability and stronger compatibility with imaging-guided procedures. This supports the broader clinical movement away from open surgery and toward more targeted intravascular solutions that aim to improve outcomes while reducing procedural trauma.

Still, this remains a specialized market. Atherectomy devices are more expensive than many standard endovascular tools, and they are often reserved for procedures where clinical complexity justifies the added cost and technique. This keeps the market meaningful, but relatively restrained in growth compared with larger vascular categories.

Market Drivers

Trend Away from Stenting

One of the most important drivers in the global atherectomy device market is the trend away from routine stenting in selected peripheral procedures. In certain lesion types, especially short lesions, physicians often prefer atherectomy combined with balloon angioplasty over placing a permanent stent. This approach can preserve future treatment options and may support good long-term patency in cases where leaving an implant is not ideal.

This shift is especially important because it changes the role of atherectomy from a niche debulking tool into a more deliberate part of vessel preparation and lesion-specific therapy. As more physicians integrate atherectomy into their treatment algorithms, unit demand benefits directly. Interest in combination therapy has also been supported by clinical data, including results from the DEFINITIVE AR study, which showed that combining directional atherectomy with drug-coated balloons improved patency in long lesions and in lesions with severe calcification. Even with changes in drug-coated balloon usage after paclitaxel concerns, the broader practice of vessel preparation continues to support atherectomy adoption.

High Stent Restenosis Rates

High rates of restenosis after stent placement are another major growth driver. Restenosis remains a common clinical problem in peripheral vascular intervention, and when it occurs, atherectomy is one of the preferred ways to reopen the vessel. This makes atherectomy relevant not only in first-time intervention, but also in repeat procedures.

Atherectomy also offers a potential advantage in cases where physicians want to reduce the vessel trauma associated with balloon dilation alone. In some procedures, balloon expansion can create dissections that contribute to the restenosis process as the vessel heals. By removing plaque rather than relying only on balloon force, atherectomy can serve as an alternative or adjunct in procedures where reducing vessel injury is a priority.

Growth in BTK Procedures in Diabetic Patients

Below-the-knee procedures are an especially important driver for the atherectomy device market. In 2022, about 35% of atherectomy procedures were performed below the knee, reflecting how relevant this category is in smaller-vessel intervention. Because stents are less likely to be placed below the knee than above the knee, atherectomy plays a more important role in these procedures.

This trend is closely linked to the rising diabetic population. Diabetic patients are more likely to develop the kind of distal peripheral disease that requires below-the-knee treatment. As this patient base grows and ages, the need for BTK intervention is expected to rise as well. That gives atherectomy a durable clinical role, especially in lesion sets where stenting is less practical and plaque modification is particularly useful.

Market Limiters

Lack of Reimbursement

The largest limiter for the atherectomy device market is lack of reimbursement, particularly in Europe. Atherectomy devices are expensive, and in many healthcare systems reimbursement does not fully support their routine use. This means physicians and hospitals often exhaust lower-cost alternatives before turning to atherectomy.

This reimbursement issue matters because atherectomy does not compete in a vacuum. It sits alongside balloon angioplasty, drug-eluting balloons and stents, all of which may be perceived as more economically practical in certain settings. As reimbursement becomes more closely tied to demonstrated clinical outcomes, atherectomy must compete not only on technical performance, but also on economic justification.

Arterial Damage and Physician Hesitation

Arterial damage is another important market limiter. Mechanical atherectomy devices can cause dissections because of their rotating and cutting action, while laser devices can occasionally damage the vessel wall if energy extends beyond the plaque. These risks have contributed to caution among physicians and have limited adoption in some settings.

In many cases, physicians may choose simpler or more familiar treatment methods if they believe those options are adequate for the lesion. This limits atherectomy use to procedures where its clinical value is clear. Although better imaging and more precise device design are improving physician confidence, the category still carries a perception of procedural complexity and risk that can limit broader adoption.

Strong Competition from Alternative Treatment Options

Atherectomy also faces competition from multiple other endovascular therapies. Drug-eluting balloons, standard balloon angioplasty and stenting all remain well-established options, and physicians can choose among them depending on lesion type, anatomy, reimbursement and personal experience. In many procedures, atherectomy is not the default option, but rather a selective one.

This competitive pressure limits the addressable market, particularly when alternative therapies are easier to justify economically or operationally. Even when atherectomy offers technical advantages, those benefits must be weighed against cost, training and procedural workflow.

Market Coverage and Data Scope

Quantitative Coverage

Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Qualitative Coverage

Market drivers and limiters, market size and growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.

Time Frame

Base year 2025, historical data to 2022 and forecasts through 2032.

Regional Coverage

North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa.

Data Types Included

Unit sales, average selling prices, procedure numbers, market size and growth trends.

This report provides both quantitative and qualitative analysis, helping users understand how procedure patterns, pricing, competitive movement and clinical practice are shaping the atherectomy device market across regions.

Markets Covered and Segmentation

• The report covers the Global Atherectomy Device Market, further segmented into:

Laser Atherectomy Devices

This segment includes laser-based systems used to ablate plaque with controlled energy delivery. These devices are particularly relevant in selected lesion types and in settings where physicians value the ability to address both soft plaque and calcified material with precision.

Mechanical Atherectomy Disposables

This segment includes disposable atherectomy devices that mechanically remove plaque through cutting, sanding or rotational action. These products are used across a range of peripheral procedures and remain the larger and more established portion of the market.

Each segment is analyzed by unit sales, average selling prices and total market value, with forecasts through 2032 and historical context to 2022.

Competitive Analysis

Abbott Vascular was the leading competitor in the peripheral atherectomy device market in 2024. Its position was strengthened by the April 2023 acquisition of Cardiovascular Systems, Inc., which added the Diamondback 360 and Stealth 360 peripheral atherectomy systems to its portfolio. Diamondback 360, a traditional rotational system, incorporates design features intended to reduce procedural side effects such as restenosis and vessel perforation. The platform is approved for both above-the-knee and below-the-knee procedures and has particularly strong adoption in the below-the-knee segment. It also benefits from higher-than-average device usage per procedure, which supports revenue strength.

Medtronic remains one of the most established competitors in the global atherectomy market. Its presence was built over time through acquisitions, including Covidien and ev3, and those transactions gave the company access to the SilverHawk line and later portfolio improvements such as HawkOne and TurboHawk. SilverHawk established a strong market foundation by using rotating blade shavers capable of removing significant plaque burden in larger vessels, especially in above-the-knee procedures. Over time, portfolio development extended into below-the-knee applications. In Medtronic's 2025 revenue mix, HawkOne led in the hospital market, followed by TurboHawk, while SilverHawk remained the lower-cost option within the family.

Philips is the leading player in laser atherectomy and built its position through the 2017 acquisition of Spectranetics. That deal added the CVX-300 Excimer and Nexcimer Laser System, along with the Turbo catheter portfolio. Turbo-Elite led in revenue performance, while Turbo-Power also contributed premium-priced sales in 2025. Philips has a distinct competitive advantage because its laser systems can address both soft plaque and calcium when combined with broader lesion management strategies. The company also benefited from growth in outpatient labs. However, the high average selling price of the CVX-300 Excimer has encouraged rental models rather than direct ownership in many accounts, which can limit wider adoption despite strong clinical capability.

Overall, the competitive landscape is shaped by acquisition-driven portfolio expansion, lesion-specific performance and the ability to support physicians across both mechanical and laser atherectomy workflows.

Technology and Practice Trends

One of the clearest trends in the atherectomy market is the move toward minimally invasive and precision-based intervention. Newer systems are being designed with better navigational control and more efficient plaque removal, which helps position atherectomy as a targeted lesion preparation tool rather than a blunt alternative to stenting.

Real-time imaging guidance is also becoming more important. As imaging quality improves, physicians are better able to identify plaque burden, lesion morphology and treatment endpoints. This supports more selective and more confident atherectomy use.

Another important trend is the growing use of atherectomy in combination procedures. Rather than using atherectomy alone, physicians increasingly pair it with balloon angioplasty and other adjunctive tools to optimize outcomes in calcified or complex lesions.

Below-the-knee intervention remains a major focus area as diabetic disease burden rises and physicians look for alternatives to stenting in smaller vessels. This supports continued innovation in devices suited for more distal anatomy.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

61 pages of detailed market analysis, segmentation and forecast data.

Methodology Appendix and Acronym Glossary.

Why This Report

Where are the most meaningful opportunities in the global atherectomy device market through 2032?

How is the shift away from stenting influencing atherectomy demand in complex and calcified lesions?

What role do below-the-knee procedures and diabetic patient growth play in long-term unit expansion?

How do reimbursement limitations and procedural risk affect adoption across regions?

Which companies lead in mechanical and laser atherectomy, and how have acquisitions changed the competitive landscape?

How are pricing, procedure mix and lesion complexity shaping market value in a slow-growth but clinically important category?

The Global Atherectomy Device Market Report from iData Research answers these questions with detailed segmentation, competitive analysis, pricing data and market forecasting. Use it to benchmark competitors, understand procedural demand and support strategy in a specialized but important peripheral vascular device segment.